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Introduction 
Varicose vein disease is a common condition affecting a significant proportion of the 
population and is known to lead to worse quality of life1, 2. Early monographs of 
venous disease and their surgical treatment date back to 1550 BC. Celcus, in first 
century Rome, proposed the concept of ligation and division of bleeding varicosities, 
while Galen, in the second century, introduced ligation and vein avulsion using 
specialised hooks3. To a large extent, these early works inspired the current surgical 
techniques used to treat varicose veins. 
Management of the condition has been transformed further over the past decade 
with surgical treatment of superficial venous incompetence no longer the mainstay of 
intervention. The introduction of endovenous thermal ablation, using either 
radiofrequency ablation (RFA) or endovenous laser ablation (EVLA), as well as 
improvement made in the use of foam sclerotherapy, however, gradually led to the 
desertion of surgery. The National Institute of Health and Clinical Excellence (NICE) 
guidelines (United Kingdom) on the management of varicose veins already 
recommend endothermal ablation as the first option to consider, relegating surgery 
only to a third line alternative4 (Table 1).  
Despite endothermal methods being accessible, uncertainty remains as to the ideal 
long-term treatment for varicose veins which would offer the best outcomes. 
 
Anatomical Success  
Modern day surgical treatment of varicose vein disease typically involves ligation of 
the saphenofemoral junction (SFJ) (high ligation) or saphenopopliteal junction (SPJ) 
with or without stripping of the truncal vein. The technique allows the instant 
elimination of reflux in the offending vein and is often carried out under general or 
regional anaesthesia.  
This type of surgical intervention has been found to be superior to ligation alone. 
Dwerryhouse et al. (1999) looked at the reoperation rate for patients having surgery 
for GSV incompetence5. This was a randomised study comparing ligation of 
sapheno-femoral (SFJ) only to SFJ ligation and stripping, and patients were initially 
followed up for five years. The rate of reoperation at 5 years was found to be 17% in 
those receiving ligation only compared to 4% in those also having stripping5. After 11 
years, the corresponding figures were 29% in the ligation only group and 11% in the 
ligation and stripping group6.  
Occlusion rate comparisons have revealed some conflicting results between surgical 
and endovenous management of varicose veins.  
In the EVOLVeS randomised controlled trial comparing RFA to surgery, in the form of 
high ligation and stripping (HL/S), Lurie et al. (2005) recruited 85 patients and 
followed them for 2 years.  Both treatment modalities were found to have comparable 
closure rates by the end of the study period7. 
However, later studies, such as another RCT comparing RFA and HL/S showed that 
endothermal ablation was superior. With 93 patients (98% CEAP class C2-3) 
randomised and treated as day-cases, all the patients receiving RFA had complete 
success of their treatment compared to 88% in those having surgery8. 
Rasmussen et al. (2007) compared another endothermal ablation technique (EVLA) 
to surgery (HL/S) in patients with C2-4 disease and found that, after 6 months, the 
occlusion rate was 98% in the ligation and stripping group and 94.4% in the EVLA 
group9. After 5 years, there were more cases of open, refluxing GSVs in the EVLA 
group compared to the surgery group (18% vs. 10%; p=NS), while there were slightly 
more recurrent varicose veins in the surgery group than the EVLA group (54.6% vs. 
46.6%; p=NS)10. The rate of re-operations was, however, comparable (38.6% in 
EVLA and 37.7% in surgery; p=NS). 
Another comparison of endovenous laser treatment and surgery (high ligation and 
stripping) showed that, at 3 months, the occlusion rate was 94% in the thermal 
ablation group compared to 87.5% in the surgical group11. 
In a prospective randomised controlled trial comparing EVLA to surgery (HL/S), 
Christenson et al. (2010) randomised 204 patients, 97% of whom were in CEAP 
class C2-C4. They found that, at 1 year and 2 years, the GSV was absent in all 
patients who had surgery12. There were 7 cases of treatment failure in the EVLA 
group (5 partial reopening and 2 complete reopening), but this did not reach 
significance (p=0.51)12. 
A comparison of the endothermal methods (RFA and EVLA), high ligation and 
stripping and ultrasound-guided foam sclerotherapy (UGFS) by Rasmussen et al. 
(2011) recruited and randomised 500 patients. Most (95%) of patients were of CEAP 
class C2-3. It showed that the failure rates (defined as an open segment of more 
than 10cm in length) at 1 year was 5.8% (RFA), 4.8% (EVLA), 4.8% (surgery) and 
16.3% (UGFS)13.  
Long-term follow-up for RFA confirms the effectiveness of this endothermal method. 
Indeed, Proebstle et al. (2015) conducted an international, prospective, multicentre 
study to investigate the effects of RF segmental thermal ablation on the GSV in 225 
patients (295 limbs)14. At 5 years, using a Kaplan-Meier method, the GSV occlusion 
rates was found to be 91.9%, while 94.9% of GSVs were found to be free from 
reflux14. 
Biemans et al. (2013) conducted an RCT comparing EVLA, UGFS and surgery and 
reported after one year. More than 90% of the study population had a CEAP class 
C2-C4. The anatomic success rate at that point for EVLA and surgery were 
comparable (88.5% vs. 88.2%), while that of UGFS was lower (72.7%)15. After 5 
years, the GSV was successfully treated/absent in 85% of legs in the surgery group, 
77% in the EVLA group and 23% in the UGFS group (p<0.001)16. At 5 years, patients 
receiving surgery or EVLA were also found to be four times more likely to have 
closure of the above-knee GSV than patients in the UGFS group16. 
The CLASS trial is an ongoing multicentre study comparing foam sclerotherapy, 
surgery and EVLA. It has recruited 795 patients (96% of them in CEAP class C2-C4) 
and preliminary results at 6 months show significantly higher closure rates in patients 
undergoing surgery (84.4%) or EVLA (83.0%) than those receiving foam 
sclerotherapy (53.6%; p<0.001) (no significant differences in closure rates between 
EVLA and surgery)17. 
The above studies demonstrate that surgery is a durable method and, at the very 
least, is comparable to endothermal methods, but superior to UGFS. However, 
anatomical success is considered more of a surrogate outcome measure, and the 
findings do not offer any indications as to the clinical or functional outcome following 
varicose vein intervention. 
 
Clinical and Quality of Life Measures 
The effect of surgery on quality of life (QoL) was investigated by Mackenzie and 
colleagues (2002) who recruited 203 patients undergoing surgery for varicose vein. 
Even though the Aberdeen Varicose Vein Symptom Severity Score (AVVSSS) was 
lower (improved) at the 4 week point, this was not significant (Wilcoxon signed rank 
test, p=0.44) until 6 months and 2 years after intervention (p=0.001)18. The same 
research group also found that the proportion of GSV removed in the thigh correlated 
with gains in QoL at 6 months and 2 years after the procedure (p=0.031 and p=0.14, 
respectively)19. They concluded that there is an improvement in QoL seen as early as 
4 weeks from the surgical procedure which continues for as long as 2 years. 
In the EVOLVeS study, the clinical score using the Venous Clinical Severity Score 
(VCSS) a few days after intervention (3 days and 1 week) showed that patients 
undergoing endothermal ablation (RFA) had a significantly more rapid clinical 
improvement than surgery, although that difference disappeared by the third week7. 
The global QoL score (using CIVIQ2) also demonstrated a worsening of the QoL in 
surgery over the first few weeks and was still present by the end of the 2 years 
follow-up.  
This early difference in clinical score was again shown in Rasmussen and 
colleagues’ study with worse VCSS in patients having surgery compared to those 
having EVLA, but this was no longer the case by the end of the first month10. QoL, as 
measured using the AVVSS, improved significantly in both groups from the 3 month 
point onwards10. 
Other studies, however, do not demonstrate such discrepancy in clinical or QoL 
scores. In their RCT, Christenson et al. found comparable improvement in both the 
EVLA group and surgery group, despite the EVLA group having a higher incidence of 
recurrence with symptoms12.  
Shadid et al. (2012) carried out a randomised controlled study comparing ultrasound-
guided foam sclerotherapy (UGFS) and surgery in the treatment of incompetent 
GSV. At the 2 year follow-up, no difference was apparent between the two groups 
with regards to VCSS or the EuroQoL’s EQ-5D20. A similar finding was observed in 
the MAGNA trial with the CIVIQ and EQ-5D scores improving in all groups (EVLA, 
UGFS and surgery) at 3 months and remaining stable  
In the CLASS trial, Brittenden et al. (2015) recruited 785 patients, randomising them 
to foam sclerotherapy, surgery or EVLA17. At 6 weeks, a greater improvement in the 
VCSS score was found in those undergoing surgery (and EVLA) compared to those 
receiving foam sclerotherapy (1.8 vs 2.2; p<0.001). This difference was no longer 
present by 6 months though. The AVVQ also showed that patients having surgery 
achieved a better QoL at 6 months compared to foam sclerotherapy (7.8 vs. 9.1; 
p<0.01). 
 
Return to Activity and Work 
Post-surgical patients tend to take longer to go back to their normal activities or work. 
Lurie and his colleagues (2003) showed that patients from the surgery group were 
back to their normal activities a mean 3.89 days after their procedure compared to a 
mean of 1.15 days for RFA (p=0.2)21. Patients were back at work a mean 4.7 days 
after their radiofrequency ablation and 12.4 days after having surgery  
When compared to EVLA, a similar picture becomes apparent. Similar differences in 
return to activities was also noted in Darwood (2008) and Subramonia’s studies118.  
Rasmussen et al. (2011) also found that patients undergoing surgery took longer to 
return to their normal activities (median 4 days compared to less than 2 days for the 
endovenous methods)13. Such a difference was no longer apparent though when the 
time to return to work was looked at with patients returning to work a median 4.3 
days following surgery compared to 3.6 days for EVLA13. 
 
Complications 
Commonly reported complications following varicose vein surgery are wound 
infections, haematoma formation, recurrence, numbness, paraesthesia, neuralgia, 
lymphatic damage, major vessel injury, residual veins and venous thromboembolism 
(deep vein thrombosis (DVT) and pulmonary embolus (PE)) 23, 24. 
In their comparative RCT, Rasmussen et al. (2011) recorded one incidence of DVT, 
5 cases of paraesthesia and 6 of hyperpigmentation in patients having surgery13. The 
rate of these latter two complications was similar to those reported for the 
endovenous procedures, however. There was a significantly higher incidence of 
phlebitis in the endovenous ablation methods (p=0.006)13. 
Christenson et al. (2010) noted significantly more cases of bruising in their surgical 
group compared to the EVLA group (15 vs. 2)12. No cases of wound infection or DVT 
were reported. 
In the MAGNA study, a significantly higher number of patients undergoing surgery 
suffered from wound infection requiring systemic antibiotics (p=0.03)15. The overall 
rate of complications was also higher with surgery, but this was not significant 
(p=0.64).  
In the CLASS trial, the surgery group had a comparable overall complication rate to 
UGFS and EVLA (3.5%, 3.8% and 3.3%, respectively) and similar serious adverse 
events related to treatment with the endovenous procedures (1.4%)17. A rather high 
incidence of numbness (15.6%) and persistent bruising (17.0%) was found to be still 
present at 6 months. 
 
 
Cost-Effectiveness 
As the cost of healthcare is increasingly becoming a worldwide issue, there is a drive 
to use the most cost-effective interventions to achieve the best outcomes in varicose 
vein disease management.  
Rasmussen et al. (2011) conducted a randomised trial comparing EVLA, RFA, UGFS 
and surgery and looked at the cost of each procedure based on the reimbursement 
rates and productivity level in Denmark. Foam sclerotherapy was found to be the 
cheapest, while both surgery and EVLA were found to be the most expensive 
treatment options13. 
The National Institute of Health and Care Excellence (NICE, United Kingdom) uses a 
threshold of £20,000 to indicate the cost-effectiveness of treatments in the National 
Health Service (NHS). In their cost-effectiveness analysis, the CLASS trial 
investigators found that, at such a ceiling, EVLA had the highest probability of being 
the most cost-effective treatment for varicose vein disease compared to surgery25. 
Cost-effectiveness analysis conducted by NICE itself showed that surgery produced 
fewer gains in quality of life years (QALYs) at an increased cost compared to the 
endothermal methods26. Despite being more costly than foam sclerotherapy, 
endothermal ablation was also found to produce the greatest QALY gain and was the 
most clinically effective treatment. The incremental cost-effectiveness ratio (ICER, 
difference in cost between two possible interventions, divided by their effect) was in 
favour of endothermal ablation, making this method the most cost-effective strategy 
in treating varicose veins26. 
 
Conclusion 
The case for the continuing use of surgical treatment options in contemporary 
practice soon becomes very apparent. It is a proven technique providing good 
anatomic success and instantaneous elimination of the cause of superficial 
incompetence. However, once clinical and quality of life scores are taken into 
account, deficiencies start appearing with this intervention, with slower improvement 
noted. Moreover, it often results in a delay before patients can resume their normal 
activities and work, and can often lead to serious complications. The cost of surgical 
intervention is also quite prohibitive and it is proving to be a less cost-effective 
treatment option compared to the endovenous methods. The choice of varicose vein 
treatment to use in current practice is dictated by its cost-effectiveness, thereby, 
making surgery increasingly harder to justify.  
Surgery, however, remains a very efficient method to treat venous incompetence and 
refinement of the technique could potentially enable it to improve some of the 
outcomes and hopefully make it a more cost viable alternative. Hence, endovenous 
ablation, most specifically endothermal methods, will be around for the foreseeable 
future, unless the newer non-thermal, non-tumescent (NTNT) methods prove to be 
more advantageous27-29. 
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